{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:24:27Z","timestamp":1791685467777,"version":"4.3.4"},"reference-count":210,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are limited. A better understanding of the pathogenesis of atopic dermatitis in recent years has contributed to the development of new therapeutic approaches that target specific pathophysiological pathways. Skin barrier dysfunction and immunological abnormalities are critical in the pathogenesis of AD. Recently, the importance of the downregulation of epidermal differentiation complex (EDC) molecules caused by external and internal stimuli has been extensively emphasized. The purpose of this review is to discuss the innovations in the therapy of atopic dermatitis, including biologics, small molecule therapies, and other drugs by highlighting regulatory mechanisms of skin barrier-related molecules, such as filaggrin (FLG) as a crucial pathway implicated in AD pathogenesis.<\/jats:p>","DOI":"10.3390\/jcm10112506","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"2506","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-1974","authenticated-orcid":false,"given":"Anna","family":"D\u0119bi\u0144ska","sequence":"first","affiliation":[{"name":"1st Department and Clinic of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, Cha\u0142ubi\u0144skiego 2a, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Deckers, I.A., McLean, S., Linssen, S., Mommers, M., van Schayck, C.P., and Sheikh, A. (2012). Investigating international time trends in the incidence and prevalence of atopic eczema 1990\u20132010: A systematic review of epidemiological studies. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039803"},{"key":"ref_5","first-page":"267","article-title":"A practical overview of pediatric atopic dermatitis, part 1: Epidemiology and pathogenesis","volume":"97","author":"Silverberg","year":"2016","journal-title":"Cutis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"21","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","first-page":"433","article-title":"Pathophysiology of atopic dermatitis","volume":"17","author":"Grobe","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/1346-8138.15664","article-title":"Basics and recent advances in the pathophysiology of atopic dermatitis","volume":"48","author":"Nakahara","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.coi.2011.09.007","article-title":"Advances in atopic dermatitis","volume":"23","author":"Novak","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yang, G., Seok, J.K., Kang, H.C., Cho, Y.Y., Lee, H.S., and Lee, J.Y. (2020). Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082867"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jaci.2017.01.039","article-title":"Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema","volume":"140","author":"Elias","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2015.06.045","article-title":"Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity","volume":"137","author":"Saunders","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2008.01.022","article-title":"Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms","volume":"121","author":"Elias","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/exd.13693","article-title":"Primary role of barrier dysfunction in the pathogenesis of atopic dermatitis","volume":"27","author":"Elias","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of Skin Barrier Dysfunction in Atopic Dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","article-title":"Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march","volume":"138","author":"Egawa","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.16934","article-title":"Atopic dermatitis: The skin barrier and beyond","volume":"180","author":"Tsakok","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjd.15065","article-title":"Skin absorption through atopic dermatitis skin: A systematic review","volume":"177","author":"Kezic","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11882-014-0433-9","article-title":"Skin barrier defects in atopic dermatitis","volume":"14","author":"Agrawal","year":"2014","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1590\/abd1806-4841.20164412","article-title":"Skin barrier in atopic dermatitis: Beyond filaggrin","volume":"91","author":"Zaniboni","year":"2016","journal-title":"Bras. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaci.2012.12.1566","article-title":"Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin","volume":"131","author":"Pellerin","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","article-title":"The role of filaggrin in atopic dermatitis and allergic disease","volume":"124","author":"Drislane","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12272-021-01305-x","article-title":"Skin barrier dysfunction and filaggrin","volume":"44","author":"Kim","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/jid.2011.393","article-title":"One remarkable molecule: Filaggrin","volume":"132","author":"Brown","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/ics.12049","article-title":"Filaggrin\u2014Rrevisited","volume":"35","author":"Harding","year":"2013","journal-title":"Int. J. Cosmet. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaci.2009.06.046","article-title":"Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens","volume":"124","author":"Scharschmidt","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.jid.5701011","article-title":"Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: Structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges","volume":"128","author":"Man","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jaci.2012.01.068","article-title":"Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice","volume":"129","author":"Kawasaki","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.06.014","article-title":"Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis","volume":"134","author":"Thyssen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/jid.2008.29","article-title":"Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum","volume":"128","author":"Kezic","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2010.10068.x","article-title":"Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age","volume":"163","author":"Flohr","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.anai.2016.03.027","article-title":"The clinical relevance of filaggrin mutations: Effect on allergic disease","volume":"117","author":"Tenn","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40521-020-00271-x","article-title":"Filaggrin gene mutations with special reference to atopic dermatitis","volume":"7","author":"Gupta","year":"2020","journal-title":"Curr Treat. Options Allergy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaci.2009.03.036","article-title":"Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease","volume":"123","author":"Baurecht","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","article-title":"The natural course of atopic dermatitis from birth to age 7 years and the association with asthma","volume":"113","author":"Illi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jdv.13871","article-title":"Compound heterozygotes for filaggrin gene mutations do not always show severe atopic dermatitis","volume":"31","author":"Sekiya","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Tintle","year":"2011","journal-title":"J. Allergy. Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1398-9995.2010.02540.x","article-title":"Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity","volume":"66","author":"Kezic","year":"2011","journal-title":"Allergy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/1523-1747.ep12338501","article-title":"Gene encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (\u201eepidermal differentiation complex\u201d) on human chromosome 1q21","volume":"106","author":"Mischke","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1600-0625.2012.01472.x","article-title":"The human epidermal differentiation complex: Cornified envelope precursors, S100 proteins and the \u2018fused genes\u2019 family","volume":"21","author":"Kypriotou","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin mutations associated with skin and allergic diseases","volume":"365","author":"Irvine","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-016-0158-5","article-title":"Genetic and epigenetic studies of atopic dermatitis","volume":"12","author":"Bin","year":"2016","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.mcp.2016.10.004","article-title":"Trying to understand the genetics of atopic dermatitis","volume":"30","author":"Stemmler","year":"2016","journal-title":"Mol. Cell Probes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.jid.5700365","article-title":"Breaking the (un)sound barrier: Filaggrin is a major gene for atopic dermatitis","volume":"126","author":"Irvine","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/bjd.12219","article-title":"Ichthyosis vulgaris: The filaggrin mutation disease","volume":"168","author":"Thyssen","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"570423","DOI":"10.3389\/fcimb.2020.570423","article-title":"Disbiotic lesional microbiome with filaggrin missence variants associate with atopic dermatitis in India","volume":"10","author":"Nath","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jid.2018.01.029","article-title":"Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans","volume":"138","author":"Margolis","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.jid.2018.05.013","article-title":"Exome Sequencing and Rare Variant Analysis Reveals Multiple Filaggrin Mutations in Bangladeshi Families with Atopic Eczema and Additional Risk Genes","volume":"138","author":"Pigors","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2133.2011.10331.x","article-title":"Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations","volume":"165","author":"Chen","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2017.09.044","article-title":"Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts","volume":"141","author":"Paternoster","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/jid.2011.342","article-title":"Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect","volume":"132","author":"Brown","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/pde.13095","article-title":"Intragenic Copy Number Variation in the Filaggrin Gene in Ethiopian Patients with Atopic Dermatitis","volume":"34","author":"Fernandez","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamadermatol.2014.4916","article-title":"Low filaggrin monomer repeats in African American pediatric patients with moderate to severe atopic dermatitis","volume":"151","author":"Quiggle","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40259-016-0157-6","article-title":"Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)","volume":"30","author":"Penner","year":"2016","journal-title":"BioDrugs"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Campofelice, A., Lentini, L., Di Leonardo, A., Melfi, R., Tutone, M., Pace, A., and Pibiri, I. (2019). Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133329"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/jid.2013.506","article-title":"Crossing barriers; restoring barriers? Filaggrin protein replacement takes a bow","volume":"134","author":"Irvine","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/jid.2013.284","article-title":"Recombinant filaggrin is internalized and processed to correct filaggrin deficiency","volume":"134","author":"Stout","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2340\/00015555-1735","article-title":"Three randomised phase I\/IIa trials of 5% cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis","volume":"94","author":"Peltonen","year":"2014","journal-title":"Acta Dermatol. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/CCID.S146760","article-title":"Feeding filaggrin: Effects of l-histidine supplementation in atopic dermatitis","volume":"10","author":"Tan","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2576S","DOI":"10.1093\/jn\/nxaa200","article-title":"l-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema)","volume":"150","author":"Gibbs","year":"2020","journal-title":"J. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155382"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e2931","DOI":"10.1038\/cddis.2017.322","article-title":"Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis","volume":"8","author":"Tsuji","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2340\/00015555-3003","article-title":"Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta Dermatol. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2011.10400.x","article-title":"Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes","volume":"165","author":"Schaupp","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cea.12023","article-title":"Cytokine regulation of the epidermal barrier","volume":"43","author":"Ogg","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/jid.2010.277","article-title":"IL-25 in atopic dermatitis: A possible link between inflammation and skin barrier dysfunction?","volume":"131","author":"Hvid","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaci.2015.01.048","article-title":"IL-33 impacts on the skin barrier by downregulating the expression of filaggrin","volume":"135","author":"Seltmann","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.08.006","article-title":"Interleukin-33 in atopic dermatitis","volume":"96","author":"Imai","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.taap.2014.08.019","article-title":"Keratinocyte-derived IL-24 plays a role in the positive feedback regulation of epidermal inflammation in response to environmental and endogenous toxic stressors","volume":"280","author":"Jin","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00281-013-0394-4","article-title":"Functions of the aryl hydrocarbon receptor in the skin","volume":"35","author":"Esser","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00403-014-1481-7","article-title":"Role of AhR\/ARNT system in skin homeostasis","volume":"306","author":"Furue","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdermsci.2015.07.011","article-title":"Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor","volume":"80","author":"Furue","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/jid.2015.6","article-title":"Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation","volume":"135","author":"Podolsky","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/toxsci\/kfs325","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated production of reactive oxygen species is an essential step in the mechanism of action to accelerate human keratinocyte differentiation","volume":"132","author":"Kennedy","year":"2013","journal-title":"Toxicol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/jid.2013.92","article-title":"Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin","volume":"133","author":"Magiatis","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.23736\/S0392-0488.18.06132-1","article-title":"Implications of tryptophan photoproduct FICZ in oxidative stress and terminal differentiation of keratinocytes","volume":"154","author":"Furue","year":"2019","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41577-019-0125-8","article-title":"The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease","volume":"19","author":"Rothhammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/jmf.2014.3396","article-title":"Antioxidant Opuntia ficus-indica Extract Activates AHR-NRF2 Signaling and Upregulates Filaggrin and Loricrin Expression in Human Keratinocytes","volume":"18","author":"Nakahara","year":"2015","journal-title":"J. Med. Food"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Hirano, A., Goto, M., Mitsui, T., Hashimoto-Hachiya, A., Tsuji, G., and Furue, M. (2017). Antioxidant Artemisia princeps extract enhances the expression of filaggrin and loricrin via the AHR\/OVOL1 pathway. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091948"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/toxsci\/kfr205","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin increases the expression of genes in the human epidermal differentiation complex and accelerates epidermal barrier formation","volume":"124","author":"Sutter","year":"2011","journal-title":"Toxicol. Sci."},{"key":"ref_88","first-page":"42","article-title":"An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway","volume":"62","author":"Tsuji","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_89","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"Bergboer","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/1346-8138.12717","article-title":"Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor","volume":"42","author":"Takei","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-4165(02)00485-3","article-title":"Functional role of AhR in the expression of toxic effects by TCDD","volume":"1619","author":"Mimura","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/imm.13120","article-title":"The IL-13-OVOL1-FLG axis in atopic dermatitis","volume":"158","author":"Furue","year":"2019","journal-title":"Immunology"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13\/IL-4\u2012JAK\u2012STAT6\/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113741"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Furue, M., Hashimoto-Hachiya, A., and Tsuji, G. (2019). Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis. Int. J. Mol. Sci, 20.","DOI":"10.3390\/ijms20215424"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"153418","DOI":"10.1016\/j.phymed.2020.153418","article-title":"Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis","volume":"81","author":"Lee","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jdermsci.2018.02.014","article-title":"Protective role of 6-formylindolo[3,2-b]carbazole (FICZ), an endogenous ligand for arylhydrocarbon receptor, in chronic mite-induced dermatitis","volume":"90","author":"Uchi","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hashimoto-Hachiya, A., Tsuji, G., Murai, M., Yan, X., and Furue, M. (2018). Upregulation of FLG, LOR, and IVL Expression by Rhodiola crenulata Root Extract via Aryl Hydrocarbon Receptor: Differential Involvement of OVOL1. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061654"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s40521-020-00259-7","article-title":"Revival of AHR Agonist for the Treatment of Atopic Dermatitis: Tapinarof","volume":"7","author":"Furue","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archdermatol.2010.34","article-title":"Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: Results from a phase 2A, randomized, placebo-controlled clinical trial","volume":"146","author":"Bissonnette","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: Results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1046\/j.0022-202x.2001.01484.x","article-title":"Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis","volume":"117","author":"Chan","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2249.2004.02649.x","article-title":"Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model","volume":"138","author":"Chen","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2008.295","article-title":"Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling","volume":"129","author":"Zheng","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1523-1747.2002.00191.x","article-title":"Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4\/interleukin-13 receptor gene: The dichotomy of extrinsic and intrinsic atopic dermatitis","volume":"119","author":"Novak","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.gene.6363985","article-title":"Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children","volume":"4","author":"He","year":"2003","journal-title":"Genes Immun."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Martin, M.J., Estrav\u00eds, M., Garc\u00eda-S\u00e1nchez, A., D\u00e1vila, I., Isidoro-Garc\u00eda, M., and Sanz, C. (2020). Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review. Genes, 11.","DOI":"10.3390\/genes11040442"},{"key":"ref_114","first-page":"13","article-title":"Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system","volume":"69","author":"Murata","year":"1999","journal-title":"Int. J. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/all.13437","article-title":"The IL-13\/periostin\/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation","volume":"73","author":"Mitamura","year":"2018","journal-title":"Allergy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Simpson","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate- to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebocontrolled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"Smith","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14712598.2021.1840548","article-title":"Current and emerging biologics for the treatment of pediatric atopic dermatitis","volume":"20","author":"Ghamrawi","year":"2020","journal-title":"Expert Opin. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/cea.12464","article-title":"The messenger between worlds: The regulation of innate and adaptive type-2 immunity by innate lymphoid cells","volume":"45","author":"Scanlon","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3389\/fimmu.2018.02694","article-title":"Social Networking of Group Two Innate Lymphoid Cells in Allergy and Asthma","volume":"9","author":"Hurrell","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Ralpha1 and IL 13Ralpha2","volume":"429","author":"Popovic","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: From basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecules cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"a028555","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to cytokine and interferons that depend upon JAKs and STATs","volume":"10","author":"Stark","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2014.10.037","article-title":"Identification of novel immune and barier genes in atopic dermatitis by means of laser capture microdissection","volume":"135","author":"Esaki","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insihgts into novel disease mechanisms with potential therapeutic implication","volume":"135","author":"Ungar","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1172\/JCI82887","article-title":"Hyperactiovation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda","year":"2016","journal-title":"J. Clin. Invsetig."},{"key":"ref_149","first-page":"e12903","article-title":"JAK\/STAT pathway modulation: Does it work in dermatology?","volume":"2","author":"Gunduz","year":"2019","journal-title":"Dermatology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Szalus, K., Trzeciak, M., and Nowicki, R.J. (2020). JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111743"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK Inhibitors for Atopic Dermatitis: An Update","volume":"20","author":"He","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"Immunotargets"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered Janus kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory reponses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J. Pharm. Exp."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Jin, W., Huang, W., Chen, L., Jin, M., Wang, Q., Gao, Z., and Jin, Z. (2018). Topical application of JAK1\/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123973"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/jdv.15301","article-title":"JAK1\/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis","volume":"33","author":"Clarysse","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10528-020-10003-0","article-title":"CYT387, a novel JAK2 inhibitor, suppresses IL-13-induced epidermal barrier dysfunction via miR-143 targeting IL-13R\u03b11 and STAT3","volume":"59","author":"Zu","year":"2020","journal-title":"Biochem. Genet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: A novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"s95","DOI":"10.25251\/skin.4.supp.95","article-title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blind Studies","volume":"4","author":"Papp","year":"2020","journal-title":"SKIN J. Cutan. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40272-019-00342-w","article-title":"New and emerging therapies for pediatric atopic dermatitis","volume":"21","author":"Nguyen","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_169","unstructured":"Timmins, P. (2020). Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine, Eli Lilly and Company. Press Release."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebocontrolled trial","volume":"145","author":"Pangan","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: Results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5021\/ad.2021.33.2.101","article-title":"Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules","volume":"33","author":"Ahn","year":"2021","journal-title":"Ann. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"941.e51","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)() TH2\/TH1 cell imbalance, whereas adults acquire CLA() TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.str.2008.06.005","article-title":"Structure of IL-22 bound to its high-affinity IL-22R1 chain","volume":"16","author":"Jones","year":"2008","journal-title":"Structure"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.4110\/in.2018.18.e42","article-title":"From Bench to Clinic: The Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis","volume":"18","author":"Jin","year":"2018","journal-title":"Immune Netw."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2019.10.005","article-title":"New treatments for atopic dermatitis targeting beyond IL-4\/IL-13 cytokines","volume":"124","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_182","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/jid.2014.141","article-title":"A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis","volume":"134","author":"Dhingra","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/exd.13467","article-title":"Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities","volume":"27","author":"Krueger","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K.M., Gulati, N., Mitsui, H., Guttman-Yassky, E., and Su\u00e1rez-Fari\u00f1as, M. (2014). IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090284"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Schaupp","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.alit.2019.12.003","article-title":"IL-24: A new player in the pathogenesis of pro-inflammatory and allergic skin diseases","volume":"69","author":"Mitamura","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.03.019","article-title":"Interleukin-24 as a target cytokine of environmental aryl hydrocarbon receptor agonist exposure in the lung","volume":"324","author":"Luo","year":"2017","journal-title":"Toxicol. Appl. Pharm."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.toxlet.2014.11.025","article-title":"Aryl hydrocarbon receptor SNP -130 C\/T associates with dioxins susceptibility through regulating its receptor activity and downstream effectors including interleukin 24","volume":"232","author":"Liu","year":"2015","journal-title":"Toxicol. Lett."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Vu, Y.H., Hashimoto-Hachiya, A., Takemura, M., Yumine, A., Mitamura, Y., Nakahara, T., Furue, M., and Tsuji, G. (2020). IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249412"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaci.2013.07.027","article-title":"Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression","volume":"133","author":"Otsuka","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2009.06.049","article-title":"Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta\/delta (but not gamma) and liver X receptor activators","volume":"125","author":"Hatano","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000336268","article-title":"Organotypic modeling of human keratinocyte response to peroxisome proliferators","volume":"196","author":"Zhang","year":"2012","journal-title":"Cells Tissues Organs"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jdermsci.2015.09.012","article-title":"Stimulation of PPAR\u03b1 normalizes the skin lipid ratio and improves the skin barrier of normal and filaggrin deficient reconstructed skin","volume":"80","author":"Wallmeyer","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Jia, T., Qiao, W., Yao, Q., Wu, W., and Kaku, K. (2019). Treatment with Docosahexaenoic Acid Improves Epidermal Keratinocyte Differentiation and Ameliorates Inflammation in Human Keratinocytes and Reconstructed Human Epidermis Models. Molecules, 24.","DOI":"10.20944\/preprints201908.0178.v1"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.anai.2018.03.013","article-title":"Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial","volume":"120","author":"Czarnowicki","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1194\/jlr.R800001-JLR200","article-title":"Thematic review series: Skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology","volume":"49","author":"Schmuth","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2014.09.035","article-title":"Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge","volume":"135","author":"Ming","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Bielach-Bazyluk, A., Zbroch, E., Mysliwiec, H., Rydzewska-Rosolowska, A., Kakareko, K., Flisiak, I., and Hryszko, T. (2021). Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Aging\u2013A Systematic Review. Cells, 10.","DOI":"10.3390\/cells10040813"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5021\/ad.2017.29.4.407","article-title":"Adiponectin Upregulates Filaggrin Expression via SIRT1-Mediated Signaling in Human Normal Keratinocytes","volume":"29","author":"Jin","year":"2017","journal-title":"Ann. Dermatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/exd.14019","article-title":"APOBEC3 regulates keratinocyte differentiation and expression of Notch3","volume":"28","author":"Dainichi","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jaci.2015.08.013","article-title":"Petrolatum: Barrier repair and antimicrobial responses underlying this \u201cinert\u201d moisturizer","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/jid.2012.42","article-title":"Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression","volume":"132","author":"Felsner","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/exd.13493","article-title":"Beyond the physico-chemical barrier: Glycerol and xylitol markedly yet differentially alter gene expression profiles and modify signalling pathways in human epidermal keratinocytes","volume":"27","author":"Ambrus","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/exd.12102","article-title":"Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms","volume":"22","author":"Hou","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e13198","DOI":"10.1111\/jfbc.13198","article-title":"Anti-atopic dermatitis effects of hydrolyzed celery extract in mice","volume":"44","author":"Che","year":"2020","journal-title":"J. Food Biochem."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Che, D.N., Cho, B.O., Shin, J.Y., Kang, H.J., Kim, J.S., Oh, H., Kim, Y.S., and Jang, S.I. (2019). Apigenin Inhibits IL-31 Cytokine in Human Mast Cell and Mouse Skin Tissues. Molecules, 24.","DOI":"10.3390\/molecules24071290"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Chu, M., Tsang, M.S., He, R., Lam, C.W., Quan, Z.B., and Wong, C.K. (2020). The Active Compounds and Therapeutic Mechanisms of Pentaherbs Formula for Oral and Topical Treatment of Atopic Dermatitis Based on Network Pharmacology. Plants, 9.","DOI":"10.3390\/plants9091166"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Ngo, H.T.T., Fang, M., Hwang, E., Kim, Y., Park, B., Seo, S.A., Do, N.Q., Nguyen, Q., and Yi, T.H. (2020). Inhibitory Effects of Urtica thunbergiana Ethanol Extract on Atopic Dermatitis-Induced NC\/Nga Mice. Antioxidants, 9.","DOI":"10.3390\/antiox9030197"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2506\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:17Z","timestamp":1760163077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":210,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10112506"],"URL":"https:\/\/doi.org\/10.3390\/jcm10112506","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]}}}